Yazar "Boz, Cavit" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Clinical and demographic characteristics and two-year efficacy and safety data of 508 multiple sclerosis patients with fingolimod treatment (vol 60, pg 23, 2023)
    (Turkish Neuropsychiatric Society, 2023) Terzi, Murat; Helvacı, Elif Merve; Şen, Sedat; Boz, Cavit; Çilingir, Vedat; Akçalı, Aylin; Beckmann, Yeşim; Uzunköprü, Cihat; Sözer, Gökçe; Terzi, Yüksel
    Copyright of Archives of Neuropsychiatry / Noropsikiatri Arsivi is the property of Turkish Association of Neuropsychiatry and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
  • Küçük Resim
    Öğe
    CORRECTION to: Clinical and demographic characteristics and two-year efficacy and safety data of 508 multiple sclerosis patients with fingolimod treatment (Archives of Neuropysychiatry, 60, 23)
    (Turkish Neuropsychiatric Society, 2023) Terzi, Murat; Helvacı, Elif Merve; Şen, Sedat; Boz, Cavit; Çilingir, Vedat; Akçali, Aylin; Beckmann, Yeşim; Terzi, Yüksel
    The name of the author Gökçe Sözer was mistakenly written as Gökçe Sezer. The correct name and institution are as follows.
  • Küçük Resim Yok
    Öğe
    Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
    (Turkiye Klinikleri, 2023) Tuncer, Aslı; Kürtüncü, Murat; Terzi, Murat; Uygunoğlu, Uğur; Göncüoğlu, Cansu; Yüceyar, Ayşe Nur; Ekmekçi, Özgül; Türkoğlu, Recai; Soysal, Aysun; Köseoğlu, Mesrure; Boz, Cavit; Beckmann, Yeşim
    Background/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients’ database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch. Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group. Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.
  • Küçük Resim
    Öğe
    Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database
    (Wiley, 2020) Tunca, Ceren; Şeker, Tuncay; Akçimen, Fulya; Coşkun, Cemre; Bayraktar, Elif; Palvadeau, Robin; Zor, Seyit; Koçoğlu, Cemile; Kartal, Ece; Şen, Nesli Ece; Hamzeiy, Hamid; Özoğuz Erimiş, Aslıhan; Norman, Utku; Karakahya, Oğuzhan; Olgun, Gülden; Akgün, Tahsin; Durmuş, Hacer; Şahin, Erdi; Çakar, Arman; Başar Gürsoy, Esra; Babacan Yıldız, Gülşen; İşak, Barış; Uluç, Kayıhan; Hanağası, Haşmet; Bilgiç, Başar; Turgut, Nilda; Aysal, Fikret; Ertaş, Mustafa; Boz, Cavit; Kotan, Dilcan; İdrisoğlu, Halil; Soysal, Aysun; Uzun Adatepe, Nurten; Akalın, Mehmet Ali; Koç, Filiz; Tan, Ersin; Oflazer, Piraye; Deymeer, Feza; Taştan, Öznur; Çiçek, Ercüment; Kavak, Ersen; Parman, Yeşim; Başak, Nazlı
    The last decade has proven that amyotrophic lateral sclerosis (ALS) is clinically and genetically heterogeneous, and that the genetic component in sporadic cases might be stronger than expected. This study investigates 1,200 patients to revisit ALS in the ethnically heterogeneous yet inbred Turkish population. Familial ALS (fALS) accounts for 20% of our cases. The rates of consanguinity are 30% in fALS and 23% in sporadic ALS (sALS). Major ALS genes explained the disease cause in only 35% of fALS, as compared with similar to 70% in Europe and North America. Whole exome sequencing resulted in a discovery rate of 42% (53/127). Whole genome analyses in 623 sALS cases and 142 population controls, sequenced within Project MinE, revealed well-established fALS gene variants, solidifying the concept of incomplete penetrance in ALS. Genome-wide association studies (GWAS) with whole genome sequencing data did not indicate a new risk locus. Coupling GWAS with a coexpression network of disease-associated candidates, points to a significant enrichment for cell cycle- and division-related genes. Within this network, literature text-mining highlightsDECR1, ATL1, HDAC2, GEMIN4, andHNRNPA3as important genes. Finally, information on ALS-related gene variants in the Turkish cohort sequenced within Project MinE was compiled in the GeNDAL variant browser (www.gendal.org).